Get the Stockscreener App
9.79
2.62%
0.25
After Hours:
9.79
Olema Pharmaceuticals Inc stock is traded at $9.79, with a volume of 1.71M.
It is up +2.62% in the last 24 hours and up +79.30% over the past month.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
See More
Previous Close:
$9.54
Open:
$9.54
24h Volume:
1.71M
Relative Volume:
2.10
Market Cap:
$671.93M
Revenue:
-
Net Income/Loss:
$-96.66M
P/E Ratio:
-4.5535
EPS:
-2.15
Net Cash Flow:
$-83.73M
1W Performance:
+11.38%
1M Performance:
+79.30%
6M Performance:
+160.37%
1Y Performance:
-18.01%
1-Day Range:
$9.445
$9.92
1-Week Range:
$8.01
$9.92
52-Week Range:
$2.86
$13.51
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Name
Olema Pharmaceuticals Inc
Sector
Industry
Phone
(415) 651-3316
Address
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
9.79 | 654.77M | 0 | -96.66M | -83.73M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Reiterated | Citigroup | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Jan-30-24 | Initiated | Citigroup | Buy |
| Jul-21-23 | Initiated | Oppenheimer | Outperform |
| May-05-23 | Initiated | CapitalOne | Overweight |
| Feb-22-23 | Initiated | Credit Suisse | Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-28-22 | Initiated | H.C. Wainwright | Neutral |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Dec-14-20 | Initiated | Canaccord Genuity | Buy |
| Dec-14-20 | Initiated | Cowen | Outperform |
| Dec-14-20 | Initiated | JP Morgan | Overweight |
| Dec-14-20 | Initiated | Jefferies | Buy |
View All
Olema Pharmaceuticals Inc Stock (OLMA) Latest News
Why Olema Pharmaceuticals Inc. stock attracts global investorsMarket Activity Report & Fast Moving Stock Watchlists - newser.com
Goldman Sachs Raises Stake in Olema Pharmaceuticals, Inc. (OLMA) - Insider Monkey
Will Olema Pharmaceuticals Inc. stock deliver better than expected guidancePortfolio Update Report & Risk Adjusted Swing Trade Ideas - newser.com
How analysts rate Olema Pharmaceuticals Inc. stock todayBull Run & Reliable Volume Spike Trade Alerts - newser.com
How to forecast Olema Pharmaceuticals Inc. trends using time series2025 Price Action Summary & Weekly Setup with High ROI Potential - newser.com
Will Olema Pharmaceuticals Inc. benefit from macro trends2025 Volatility Report & Fast Entry and Exit Trade Plans - newser.com
11 Best Fast Money Stocks to Buy Now - Insider Monkey
Chart based exit strategy for Olema Pharmaceuticals Inc.2025 Top Decliners & Free High Return Stock Watch Alerts - newser.com
What analysts say about Olema Pharmaceuticals Inc stockVolume Weighted Average Price & Low Risk Portfolio Growth - earlytimes.in
What drives Olema Pharmaceuticals Inc stock priceVolume Spike Alerts & Accelerated Financial Growth - earlytimes.in
Olema Pharmaceuticals (NASDAQ:OLMA) Trading 6.5% HigherHere's Why - MarketBeat
Olema Pharmaceuticals, Inc. $OLMA Stake Raised by Goldman Sachs Group Inc. - MarketBeat
Oppenheimer Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $22 - 富途牛牛
Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Up 10.2%Time to Buy? - MarketBeat
Applying chart zones and confluence areas to Olema Pharmaceuticals Inc.Quarterly Portfolio Review & Fast Gaining Stock Reports - newser.com
Cyrus Harmon Sells 10,000 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Director Cyrus Harmon Sells 10,000 Shares - MarketBeat
Analyst Calls: Is Olema Pharmaceuticals Inc forming bullish engulfing patterns2025 Analyst Calls & Community Consensus Trade Alerts - خودرو بانک
This Insider Has Just Sold Shares In Olema Pharmaceuticals - simplywall.st
What’s the recovery path for long term holders of Olema Pharmaceuticals Inc.Weekly Trade Recap & Scalable Portfolio Growth Methods - newser.com
Aug Ideas: Should I invest in Olema Pharmaceuticals Inc before earningsDay Trade & Free Growth Oriented Trading Recommendations - خودرو بانک
Key resistance and support levels for Olema Pharmaceuticals Inc.Weekly Profit Analysis & Expert Curated Trade Setup Alerts - newser.com
Sentiment analysis tools applied to Olema Pharmaceuticals Inc.Quarterly Trade Summary & Trade Opportunity Analysis Reports - newser.com
Olema Pharmaceuticals Inc. stock prediction for this weekBreakout Watch & Technical Entry and Exit Tips - newser.com
Visual analytics tools that track Olema Pharmaceuticals Inc. performanceWeekly Trade Recap & AI Based Buy/Sell Signal Reports - newser.com
Highs Report: Does Olema Pharmaceuticals Inc outperform in volatile markets2025 Breakouts & Breakdowns & Weekly Top Performers Watchlists - خودرو بانک
What candlestick patterns are forming on Olema Pharmaceuticals Inc.2025 Winners & Losers & High Win Rate Trade Tips - newser.com
Buy Signal: Is Olema Pharmaceuticals Inc stock a top performer YTDJuly 2025 PostEarnings & Capital Protection Trading Alerts - خودرو بانک
Olema Pharmaceuticals Inc Stock (OLMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):